For the quarter ending 2025-09-30, ACLS had $13,847K increase in cash & cash equivalents over the period. $43,335K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 25,986 | 59,955 |
| Depreciation and amortization | 4,328 | 8,824 |
| Deferred income taxes | 2,399 | -4,155 |
| Stock-based compensation expense | 5,344 | 10,324 |
| Provision for excess and obsolete inventory | 883 | 1,742 |
| Accretion of discounts and premiums on short-term and long-term investments | 1,081 | 2,254 |
| Unrealized currency gain on foreign denominated transactions | -4,578 | 6,807 |
| Mark-to-market adjustment on forward exchange contracts | -128 | -457 |
| Accounts receivable | 8,695 | -67,459 |
| Inventories | 17,488 | 16,760 |
| Prepaid expenses and other current assets | -2,148 | -1,175 |
| Accounts payable and other current liabilities | 29,708 | -28,343 |
| Deferred revenue | -482 | -9,581 |
| Income taxes | 214 | 1,966 |
| Other assets and liabilities | 2,620 | 4,480 |
| Net cash provided by operating activities | 45,350 | 79,522 |
| Expenditures for property, plant and equipment and capitalized software | 2,015 | 6,945 |
| Purchases of short-term and long-term investments | 161,452 | 345,174 |
| Maturities and sales of short-term investments | 164,845 | 387,975 |
| Net cash provided by (used in) investing activities | 1,378 | 35,856 |
| Net settlement on restricted stock grants | -104 | -4,152 |
| Repurchase of common stock | 32,335 | 63,515 |
| Proceeds from employee stock purchase plan purchases | 0 | 1,246 |
| Principal payments on finance lease obligation | 336 | 676 |
| Net cash used in financing activities | -32,775 | -67,097 |
| Effect of exchange rate changes on cash and cash equivalents | -106 | 1,935 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 13,847 | 50,216 |
| Cash and cash equivalents at beginning of period | 131,064 | - |
| Cash and cash equivalents at end of period | 195,127 | - |
AXCELIS TECHNOLOGIES INC (ACLS)
AXCELIS TECHNOLOGIES INC (ACLS)